Subsequently, we examined LPAR2 expression using UALCAN and found that the mRNA expression levels of LPAR2 were significantly higher in BLCA, BRCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CECS), glioblastoma multiforme (GBM), HNSC, KIRC, kidney renal papillary cell carcinoma (KIRP), LIHC, LUAD, LUSC, PRAD, READ, STAD, and UCEC than in normal control tissues (Figs. 2C, 3). The gene discussed is LPAR2; the disease is bladder transitional cell carcinoma.